Keywords: Mylan first-quarter 2011 financial results
Mylan's 1st-qtr 2011 adjusted diluted EPS up 22%, in line with forecasts
Article | 04 May 2011
US generics group Mylan (Nasdaq: MYL) reported that total revenues for the quarter ended March 31, 2011 increased 12.1% to $156.6 million. Total revenues ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
